Q-omics provides the consensus-scored MTCYBP17 profile across patient tissues and cancer cell-line models. MTCYBP17 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LUSC. Additionally, MTCYBP17 RNA expression shows 2,879 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight LUSC, and KIRC as cancer lineages where MTCYBP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.